Sentences with phrase «from vaccine trials»

In their new study, researchers from the Johns Hopkins Bloomberg School of Public Health, Imperial College London and the University of Florida re-analyzed data from vaccine trials conducted in 10 countries with more than 30,000 participants as well as recently published data on the long - term follow - up of these participants.

Not exact matches

He says that in animal trials, a vaccine against dengue protected «a hundred percent of animals from a pathogenic dengue challenge.»

We talk with two pioneering physicians — one of whom is overseeing the world's largest HIV vaccine trial and the other led a groundbreaking successful pilot in the U.S. — to see how far we are from getting to zero.

Drugs that are specific to hepatitis C will soon go from trial to clinic, giving more patients hope, but a vaccine is still elusive

Vaccine proponents also point to the lessons learned from the failed Merck STEP trial.

So say scientists at Merck, who learned from trials in 2007 that their vaccine, based on a live, weakened adenovirus carrying genes for HIV proteins, was ineffective.

In a clinical trial, this vaccine protected 45 percent of the adults who received the highest dose against infection from H5N1.

A retrospective analysis of those who participated in phase III trials in 2011 found that those who had never had a dengue infection at the time of vaccination were in rare cases at risk of enhanced disease, although the Dengvaxia vaccine did reduce infections and cases of serious illness in those who had previously suffered from dengue.

The so - called STEP trial, sponsored by pharmaceutical giant Merck & Co. and the federally funded HIV Vaccine Trials Network (HVTN), was the first to test the idea of stimulating the immune system's killer T cells to hunt for the virus more aggressively, in this case using a weakened form of the cold virus to carry three genes from HIV.

In the coming months, scientists will have to evaluate the trial's full data to determine why the vaccine failed: Were the infecting viruses too different from the vaccine strain to offer resistance?

The first vaccine to receive the green light for human trials is a product from Pennsylvania - based Inovio Pharmaceuticals.

That's because a trial like this one is almost without precedent in modern medical research: It involves giving children a vaccine that is almost certain not to benefit them, and that might harm them, all to protect other children from an unlikely scenario — a large - scale anthrax attack.

With HIV, progress has been slow, but we have a glimmer of hope now from the so - called RV144 trial in Thailand, in which an experimental HIV vaccine turned out to be about 30 percent effective.

The vaccine from the Mount Sinai researchers is entering the first human safety trials with drugmaker GlaxoSmithKline.

The company is starting larger trials to see if the vaccine can actually protect people from getting sick.

In 2011, Science's editors will be watching a smaller detector at the Large Hadron Collider called LHCb, which will study B mesons in great detail; new techniques that should lead to the discovery of many more genes contributing to adaptation; an ignited fusion burn at the National Ignition Facility; broadly neutralizing antibodies, which are capable of disabling a wide range of viral variants; the first plug - in hybrid electric cars whose batteries are charged from a wall socket go on the market; and the results of the first phase III trial of a malaria vaccine.

China has not approached the WHO about the trial but the WHO says it has been kept informed by United Biomedical, and has seen the results from animal tests of the vaccine.

CDC based its decision for children under 10 to receive two doses on preliminary data from clinical trials of the vaccines being used in the United States, but he said more complete data should emerge soon.

«The findings reported are derived from an artificial in vitro experimental system and do not appear to be consistent with the data obtained by two independent groups utilising samples from the human clinical trials of the actual Merck Ad5 HIV vaccine.»

Granted, different vaccines are in use in different locales, but the differences reflect that data from clinical trials of various vaccines in a range of age brackets is still preliminary.

NicVAX, an antismoking vaccine that recently received $ 10 million in funding from NIDA, is in large clinical trials under the auspices of its maker, Nabi Biopharmaceuticals.

«[T] he visit also comes as the White House awaits action from Congress on a nearly $ 6.2 billion emergency appropriations request to continue fighting [Ebola] in West Africa and to move candidate vaccines through clinical trials.

[NIAID Director Anthony] Fauci says $ 56 million of the total would go toward a larger efficacy trial in Liberia, which would include both the NIAID / GSK [GlaxoSmithKline] vaccine and another made by NewLink Genetics of Ames, Iowa (pending more data from ongoing safety trials).»

This clinical trial, which included 1,518 participants, was the basis for the recent approval from the Food and Drug Administration of a 2 - dose series of the 9 - valent HPV vaccine for adolescents,» writes Lauri E. Markowitz, M.D., of the U.S. Centers for Disease Control and Prevention, Atlanta, and colleagues in an accompanying editorial.

«With data from the trial reported in JAMA, evidence now supports a 2 - dose schedule in adolescents (aged 9 to 14 years) for all 3 licensed HPV vaccines.»

The data obtained from this study provide a basis for more rapid, cost - effective clinical trials to evaluate new influenza drugs or to determine the efficacy of candidate vaccines for both seasonal and pandemic influenza.

«The findings from this trial are very encouraging to those of us who have spent many years working on vaccine candidates to protect against dengue, a disease that is a significant burden in much of the world and is now endemic in Puerto Rico,» said Stephen Whitehead, Ph.D., of NIH's National Institute of Allergy and Infectious Diseases (NIAID).

A clinical trial in which volunteers were infected with dengue virus six months after receiving either an experimental dengue vaccine developed by scientists from the National Institutes of Health (NIH) or a placebo injection yielded starkly contrasting results.

Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees.

Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.

Vaccine developers are trying to improve vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu vaccine in patients on immune - suppressiveVaccine developers are trying to improve vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu vaccine in patients on immune - suppressivevaccine in patients on immune - suppressive drugs.

The vaccine that has been tested in the United States was made from a cold - causing chimpanzee adenovirus that had been engineered to express proteins from two species of the Ebola virus, known as Zaire and Sudan (after their origins), and that was already available when the trial began in early September.

They examined 936 HIV sequences collected from 44 trial participants who received the vaccine and became infected, and 66 people who got the placebo.

In WRAIR's first vaccine trial, all the participants were «my friends in the laboratory or from down the hall,» says Ballou, and they went home after being infected.

In a few weeks, meeting participants learned, enough data may be available from small phase I trials of a vaccine jointly made by the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline (GSK) that began in September to launch efficacy studies.

Up until now, efforts in generating a vaccine against TB have been mainly focused on T cells (cells from the adaptive arm of our immune response with memory capacity), with very disappointing outcomes in both pre-clinical as well as clinical trials.

The U.K. government also noted that «affected African countries will have the primary role of authorising or allowing use of investigational vaccines» and said «buy in» from those communities about the clinical trials must be obtained as soon as possible.

Merck began a second trial of its vaccine in February in South Africa, where the circulating virus differs from the one the vaccine is based on.

Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro - Oncology and accompanied by an editorial highlighting the importance of the trial.

In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response.

Those who oppose the trial think the approach with the greatest chance of success would be to test a vaccine based on one subtype in a population at risk from the same subtype.

The eagerly awaited results from the world's first large - scale trial of a malaria vaccine are in, and they confirm what other, smaller studies had shown: The vaccine, called RTS, S, offers partial protection, cutting episodes of malaria in babies and toddlers in half.

The latest data from a large clinical trial of Merck's cervical cancer vaccine, Gardasil, found it offered 100 % protection against cervical, vulval and vaginal diseases, caused by HPV (types 6, 11, 16 and 18) and 98 % protection against advanced pre-cancers caused by HPV types 16 and 18 (New England Journal of Medicine: vol 356, p1915).

In October at the WHO in Geneva, scientists and activists from developing and industrialised countries agreed that, despite the American decision, trials of the two vaccines could be justified in countries hit hard by HIV, provided that their governments approved (This Week, 22 October 1994).

The army landed $ 20 million for a trial of an AIDS vaccine after heavy lobbying, in part from the company that makes the vaccine.

The trial would carefully evaluate safety, but this time there will be no control group because withholding the vaccine from some participants is no longer seen as ethical.

White MT, Verity R, Griffin JT, et al.White MT, Verity R, Griffin JT, Asante KP, Owusu - Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC close, 2015, Immunogenicity of the RTS, S / AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infectious Diseases, Vol: 15, ISSN: 1473 - 3099, Pages: 1450 - 1458

Secondly, the Jenner will develop its transcriptomics core facility to carry out RNAseq analysis of clinical samples (both blood and bronchoalveolar lavage fluid) from trials with novel TB, malaria and Ebola vaccines.

The Jenner will provide RNAseq and / or bioinformatics analysis of pre-existing transcriptomics data for up to 200 samples from vaccine clinical trials.

Phase III trials involve thousands of participants and occur only after the experimental vaccine has successfully moved from a Phase I and Phase II trial.